At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised, Double-Blinded, Double-Dummy, Placebo-Controlled, MultiCentre-, Six-Way, Crossover Study to Assess the Pharmacodynamics, Pharmacokinetics, and Safety of Abediterol Single Dose, Given by Dry Powder Inhaler (DPI) or Pressurised Metered-Dose Inhaler (pMDI), in Patients With Asthma on Inhaled Corticosteroids.
In Brief
A Phase 1 clinical trial evaluating Abediterol 0.156 μg, Abediterol 2.5 μg, and 2 other interventions for Asthma. Completed, enrolled 30 participants across 4 sites.
Detailed Summary
The purpose of this study is to investigate the pharmacodynamics of single doses of abediterol given by 2 different devices in participants with asthma. Abediterol (AZD0548) is a potential for once daily treatment of asthma and chronic obstructive pulmonary disease (COPD) in fixed dose combination (FDC) with an inhaled corticosteroid (ICS) or a novel anti-inflammatory agent. The aim of the clinical studies is to enable further investigations in participants with asthma and COPD to evaluate and develop abediterol as an effective long acting bronchodilator with an acceptable safety profile compared to other inhaled bronchodilators on the market, for the treatment of asthma and COPD.
Study Details
Timeline
Interventions
Dry powder for inhalation
Dry powder for inhalation
Pressurised metered-dose inhaler
Pressurised metered-dose inhaler
Pressurised metered-dose inhaler
Pressurised metered-dose inhaler and dry powder for inhalation.